Press release
Bioprocess Automation and Control Software Market to Reach US$ 13.59 Billion by 2032 as Smart Biomanufacturing, GMP Control and Real-Time Process Optimization Scale
bioprocess-automation-and-control-software-market
Request Executive Sample | Market Intelligence: https://www.datamintelligence.com/download-sample/bioprocess-automation-and-control-software-market?kailas
2026 Official Developments in Bioprocess Automation Platforms, GMP Software, Facility Digitalization and CDMO Deployments
- Emerson released DeltaV version 16.LTS in January 2026. The update added software-defined control, wider enterprise data visibility, stronger cybersecurity and tighter integration between control-layer data, historians, analytics and AI.
- Cytiva and Rockwell Automation launched Figurate SCADA in April 2026. The platform connects Cytiva equipment, third-party instruments and Rockwell's FactoryTalk suite through an open architecture. It is designed to scale from process development to commercial production while supporting centralized alarms, batch reporting and cGMP workflows.
- Agilent introduced OpenLab Sync in May 2026. The laboratory execution system converts static procedures into guided, traceable digital workflows and supports standardized execution across regulated sites. Its AI-enabled functions extend digital execution into laboratory and quality operations.
- Eppendorf issued security-focused BioFlo controller updates in May 2026. Revisions for the BioFlo 120 and BioFlo 320 removed Virtual Network Computing access, showing that bioprocess digitalization requires lifecycle cybersecurity management as well as process performance.
- Sartorius advanced its integrated digital bioprocess architecture in 2026. Its Biobrain framework connects equipment control, supervision, operator orchestration and electronic batch records, while the Umetrics Digital Twin AI Ecosystem supports predictive modeling, deviation detection and real-time optimization.
Software Is Becoming the Scale-Up Layer
Bioprocess automation and control software monitors biological production while creating the electronic evidence needed to show that each batch was executed correctly. It can manage critical process parameters such as temperature, pH, dissolved oxygen, pressure, flow and agitation while connecting them with recipes, alarms, operator actions and quality records.
This role becomes more important as manufacturers move from development vessels to commercial bioreactors, adopt single-use equipment or transfer processes between internal sites and CDMOs. A process that works at one scale can fail during transfer when control logic, data structures or equipment interfaces change. A consistent digital architecture reduces that risk by preserving process definitions and contextualized data across the product lifecycle.
Intensified and continuous processes also operate within narrower control windows. Process analytical technology, soft sensors and real-time analytics can detect drift before a specification is breached, but only when instruments and data platforms are integrated with the control system.
Request a Customized Report According to Your Business Strategy: https://www.datamintelligence.com/customize/bioprocess-automation-and-control-software-market?kailas
Compliance Is Moving From Documentation to Execution
Electronic batch records, manufacturing execution systems and digital workflows can reduce transcription errors, accelerate review and make deviations easier to investigate. However, replacing paper does not automatically create compliant manufacturing.
Systems must be validated for their intended use, user access must be controlled, audit trails must be reviewable and records must remain complete, consistent and accurate. FDA guidance identifies data integrity as a core CGMP requirement, while European computerized-system rules emphasize risk management, security, electronic records and controlled system lifecycles.
The main adoption barriers include:
- Proprietary interfaces in legacy equipment
- Paper or hybrid records that fragment process history
- Validation and change-control costs
- Inconsistent data models across sites
- Cybersecurity exposure between IT and operational technology
- Limited bioprocess automation expertise
AI process control adds opportunity and risk. Predictive models can recommend setpoints, detect anomalies and support real-time release, but regulated use requires controlled training data, model governance and evidence that updates do not compromise product quality.
Market Segmentation Reflects the Connected Manufacturing Stack
DataM Intelligence segments the market by software type into bioprocess control software, data-management and analytics software, quality management software, laboratory information management systems and manufacturing execution systems. Deployment models include on-premises, cloud-based and hybrid systems. Applications span upstream and downstream processing, monitoring, R&D, process development, optimization and scale-up. End users include biopharmaceutical companies, pharmaceutical manufacturers, contract manufacturing organizations and research institutions.
The larger opportunity lies in connecting SCADA and distributed control systems with MES, digital batch records, laboratory systems, QMS platforms and enterprise analytics. Hybrid deployment is especially relevant because manufacturers may need cloud-scale analysis while retaining validated, low-latency control inside the facility.
Regional Manufacturing Priorities Shape Adoption
The USA combines a large biotechnology base with strict CGMP and electronic-record expectations, encouraging investment in validated automation, data-integrity controls and scalable CDMO networks.
Japan places strong emphasis on GMP inspection and documented manufacturing controls, making validated implementation, supplier support and controlled technology transfer important for local deployments.
Germany operates within the EU GMP framework for computerized systems and offers a strong pharmaceutical-engineering environment for MES modernization, modular production and cross-site standardization.
South Korea combines expanding biologics capacity with formal pharmaceutical GMP requirements, creating demand for platforms that support high-throughput production, traceable records and post-approval process control.
Purchase Corporate License | Market Intelligence: https://www.datamintelligence.com/buy-now-page?report=bioprocess-automation-and-control-software-market?kailas
Leading Companies Are Competing on Integration Depth
Emerson positions DeltaV as an integrated control, MES, historian and analytics environment. Its 2026 release strengthens its value for manufacturers seeking one architecture that can scale from unit operations to enterprise visibility.
Cytiva combines bioprocess equipment, automation and digital solutions. Figurate SCADA matters because it addresses multi-vendor interoperability and offers a common path from development to commercial manufacturing.
Sartorius connects Biobrain process control with supervision, operator guidance, electronic records and Umetrics analytics, supporting process intensification and predictive digital biomanufacturing.
Eppendorf provides bioreactors, controllers and software for upstream development and scale-up. Its 2026 updates demonstrate the importance of cybersecurity and software support throughout the installed system lifecycle.
Production Readiness Will Depend on Digital Readiness
The strongest automation investments will reduce scale-up risk, shorten batch review, improve process visibility and create reusable digital standards across products and sites. Purchasing isolated software without an integration, validation and data-governance strategy can simply replace paper silos with digital ones.
In the bioprocess automation and control software market, competitive advantage will come from platforms that connect process science, equipment execution, quality oversight and enterprise learning. For biologics manufacturers and CDMOs, digital readiness is becoming a direct measure of production readiness.
Read Exclusive Report Description: https://www.datamintelligence.com/research-report/bioprocess-automation-and-control-software-market
Contact:
Fabian Mathew
DataM Intelligence 4market Research LLP
6th Floor, M2 Tech Hub, DataM Intelligence 4market Research LLP, Lalitha Nagar, Habsiguda, Secunderabad, Hyderabad, Telangana 500039
USA: +1 877-441-4866
Email: fabian@datamintelligence.com
About DataM Intelligence
DataM Intelligence is a global market research and business intelligence firm delivering actionable insights across healthcare, pharmaceuticals, chemicals, energy, technology, food, and industrial sectors. Through syndicated reports, custom research, consulting, and competitive intelligence services, the company helps organizations identify growth opportunities, navigate market challenges, and make informed strategic decisions in over 50+ countries worldwide.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Bioprocess Automation and Control Software Market to Reach US$ 13.59 Billion by 2032 as Smart Biomanufacturing, GMP Control and Real-Time Process Optimization Scale here
News-ID: 4574271 • Views: …
More Releases from DataM intelligence 4 Market Research LLP
Lithium-Ion Battery Anode Market to Reach US$ 273.0 Billion by 2033 as EVs, Sili …
The global lithium-ion battery anode market reached US$26.3 billion in 2025 and is projected to reach US$273.0 billion by 2033, expanding at a CAGR of 34% during 2026-2033, according to DataM Intelligence. Anode materials are becoming a decisive lever in lithium-ion cell design because they directly influence charging speed, energy density, cycle life, safety and battery cost. As electric vehicles and energy-storage systems scale, the market is shifting from conventional…
Adeno Associated Virus Vectors Manufacturing Market to Reach USD 5.07 Billion by …
The global adeno-associated virus vectors manufacturing market reached US$1.62 billion in 2025 and is projected to reach US$5.07 billion by 2033, expanding at a CAGR of 18% during 2026-2033, according to DataM Intelligence. AAV manufacturing has become a decisive constraint in gene therapy development because clinical success cannot translate into treatment access without consistent vector yield, verified potency, acceptable full-capsid content and a production process capable of moving from small…
NASH/MASH Treatment Market to Reach US$ 33.02 Billion by 2033 as Resmetirom, GLP …
The global NASH or MASH treatment market reached US$8.13 billion in 2025 and is projected to reach US$33.02 billion by 2033, expanding at a CAGR of 17.55% during 2026-2033, according to DataM Intelligence. The category is moving beyond lifestyle-led management into drug-based care for patients with noncirrhotic metabolic dysfunction-associated steatohepatitis and clinically meaningful fibrosis. Commercial growth will depend not only on drug efficacy, but also on finding eligible patients, confirming…
Battery Management Integrated Circuit IC Market to Reach USD 17.46 Billion by 20 …
The global battery management integrated circuit IC market is projected to increase from US$10.10 billion in 2026 to US$17.46 billion by 2033, expanding at a CAGR of 8.1% during 2026-2033, according to DataM Intelligence. Battery management ICs are becoming the semiconductor control layer behind battery safety, range estimation, cell balancing, fast charging, thermal supervision and lifecycle monitoring. As electric vehicles, energy storage systems and portable electronics adopt larger and more…
More Releases for GMP
IMARC Engineering Enhances GMP Readiness Assessment Through GMP Compliance Audit …
Good Manufacturing Practice compliance in India has moved from a paperwork exercise to a business-critical priority. Regulatory tightening under the revised Schedule M framework has raised the bar for infrastructure, documentation, and quality systems across pharmaceutical, food, and healthcare manufacturing.
A GMP readiness assessment finds the gaps before a regulator, buyer, or certification body does. IMARC Engineering's GMP Compliance Audit Services convert scattered documentation and ad-hoc practices into an audit-ready quality…
Creative Peptides Released GMP Synthesis Service
Located in Shirley, New York, the world’s leading peptide supplier Creative Peptides announced the launch of its GMP synthesis (https://www.creative-peptides.com/services/custom-gmp-peptide-synthesis-services.html ) business on August 29, 2018. Now this company is focused on the development and GMP manufacturing of pharmaceutical grade peptides.
As the demand of pharmaceutical market continues to grow, more and more pharmas and research institutions choose the CMO and CRO models to expand their businesses, which is more…
ECA Foundation releases free GMP WebApp
The ECA Foundation has been providing advanced training and information services in the pharmaceutical industry and especially with regard to pharmaceutical Quality Assurance and GMP compliance for more than 10 years. Now the organisation took advantage of its extensive experience to develop a further free of charge service – the new GMP WebApp.
This new GMP WebApp runs on all smartphones and tablet PCs (Apple and Android platforms) and allows users…
GMP Friction Products Awarded ISO 9001:2008
Internationally Recognized Certification Measures Consistency in Process, Procedure and Quality Performance in Manufacture of Friction Materials
AKRON, OH (March 23, 2011) -- GMP Friction Products, a world leader manufacturing powdered metal friction products for clutch plates and brake pads, recently received certification for ISO 9001:2008.
“ISO 9001:2008 signifies we have taken the extra measure of documenting the policies and standards to ensure consistent compliance with our manufacturing processes,” said Jerry Lynch,…
GMP MANUAL Volume 2 - Validation Procedures by Maas & Peither AG – GMP Publish …
GMP Publishing is launching its new GMP MANUAL Volume 2 – Validation Procedures.
The compendium on validation procedures was written by Dr. Doris Borchert, Dr. Peter Bosshard, Dr. Ralph Gomez, Dr. Michael Hiob, Dr. Christine Oechslein, Max Lazar, Ulrike Reuter, Michael Schulte, Uwe Schwarzat – all international experts and key opinion leaders. They share their detailed understanding of the various aspects of the validation process in clear and comprehensive style…
blue inspection body celebrates 50 GMP audits
Münster (Germany), 20 November 2009. Two years after founding the company and just 18 months after gaining the accreditation blue inspection body GmbH announced today the successful execution of its 50th GMP audit. Further audit trips to China, India, Israel and various European countries have been scheduled already, meaning that in the first quarter 2010 the 75th audit is targeted to be completed. Blue, as a privately organised inspection body,…
